Literature DB >> 12601099

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study.

M Doder1, E A Rabiner, N Turjanski, A J Lees, D J Brooks.   

Abstract

BACKGROUND: The pathophysiologic mechanisms underlying parkinsonian tremor remain unclear. The response to dopaminergic treatment is variable and nondopaminergic mechanisms may play a role in tremor generation. Midbrain raphe 5-HT(1A) binding provides a functional measure of serotonergic system integrity. With PET, the aim of this study was to examine regional cerebral (11)C-WAY 100635 binding to 5-HT(1A) receptors in patients with PD and to correlate it with severity of tremor.
METHODS: (11)C-WAY 100635 PET was performed on 23 patients with PD and eight age-matched healthy volunteers. Brain 5-HT(1A) receptor binding was computed using compartmental modeling with a cerebellar reference tissue input function.
RESULTS: The authors found mean 27% reduction in the midbrain raphe 5-HT(1A) binding potential in patients with PD compared to healthy volunteers (p < 0.001). They also showed that Unified Parkinson's Disease Rating Scale composite tremor scores, but not rigidity or bradykinesia, correlate with 5-HT(1A) binding in the raphe (p < 0.01).
CONCLUSIONS: These findings support previous indirect evidence that serotonergic neurotransmission is decreased in PD in vivo. The authors hypothesize that the reduction in raphe 5-HT(1A) binding represents receptor dysfunction or loss of cell bodies due to Lewy body degeneration in PD, or both. An association between 5-HT(1A) receptor availability in the raphe and severity of parkinsonian tremor was also found.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601099     DOI: 10.1212/01.wnl.0000031424.51127.2b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  62 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

3.  Are we making progress in the understanding of tremor in Parkinson's disease?

Authors:  Mark Hallett; Günther Deuschl
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

4.  Diagnostic aspects of early Parkinson's disease.

Authors:  Thomas Müller; Gerd Fuchs; Matthias Hahne; Wolfgang Klein; Michael Schwarz
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

5.  Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.

Authors:  David J Brooks
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

6.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

Review 7.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

8.  Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.

Authors:  V Caretti; D Stoffers; A Winogrodzka; I-U Isaias; G Costantino; G Pezzoli; C Ferrarese; A Antonini; E-Ch Wolters; J Booij
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

9.  Persistence of associations between cognitive impairment and motor dysfunction in the early phase of Parkinson's disease.

Authors:  Magdalena E Domellöf; Lars Forsgren; Eva Elgh
Journal:  J Neurol       Date:  2013-05-29       Impact factor: 4.849

Review 10.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.